An impurity formed during a chemical reaction ultimately needs to be purged. As you aim for simplification, efficiency, and minimizing operations in scaling up the chemistry, this challenge becomes magnified the longer it persists. While optimizing reaction conditions may be your first instinct, why not try this in parallel: obtain a full solubility profile of the impurity across a variety of conditions. By comparing the impurity solubility profile with the solubility data for the reaction product, the path to simple purification could be right in front of you, saving time and unnecessary lab work.
If you haven’t experimentally collected the solubility data for all the compounds in your route – it’s not too late. A solvent screen with SPA® requires only microscopic material and can be run at various temperatures to provide the most useful insights. By including aqueous media, extraction solvents, and other solvent systems in the screen you can minimize loss in the water layer, avoid unnecessary phase separations, select appropriate volumes and reduce losses in the mother liquor.
In the laboratory, these gains will improve efficiency – as you scale, these insights will have maximum impact.
Don’t wait until it’s too late – have the right data package early to streamline your program and avoid bottlenecks – talk to our experts.
The Solubility Company’s proprietary SPA® technology measures physicochemical properties essential to drug discovery and development. As an optical technique, it requires no knowledge of chemical structure and is performed on microgram scale to provide actionable data as early as possible. With sites in the US and Finland, we can receive samples at the most convenient location to begin your project. With applications spanning lead optimization, R&D, formulation, and chemical process development, this powerful tool integrates as part of a holistic approach towards supporting new drug development.
If you’re looking to Research Smart and Deliver Early, click here to drop us a message!
Viikinkaari 4
00790 Helsinki
FINLAND
1 Broadway
Cambridge MA 01242
United States
Workshop: Mitigating Risk in Small Molecule Drug Development
6 February 2025, MassBioHub, Cambridge, MA